[DOI] [PubMed] [Google Scholar] 108.Jafarian I., Eskandari M.R., Mashayekhi V., Ahadpour M., Hosseini M.J
Scientists are pursuing a number of theories including oxidative stress, glutamate toxicity, and mitochondrial dysfunction (Rowland 1994
Curr Drug Metab 8(4):297306 Mishra SR, Mahapatra KK, Behera BP, Patra S, Bhol CS, Panigrahi DP et al (2021) Mitochondrial dysfunction as a driver of NLRP3 inflammasome activation and its modulation through mitophagy for potential therapeutics
In 2022, a novel GLP-1 analog, semaglutide was introduced as an anti-obesity drug
If the question is "what does the science suggest is coming," retatrutide's phase 2 weight-loss and liver-fat numbers are genuinely notable but "promising in phase 2" and "proven and approved" are very different standards, and the gap between them is exactly what phase 3 exists to test